At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 110 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 1.4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment
In Brief
A Phase 4 clinical trial evaluating Atomoxetine and Placebo for Attention Deficit Hyperactivity Disorder and Dyslexia. Completed, enrolled 110 participants across 1 site.
Detailed Summary
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder, Dyslexia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartSep 2008
Primary CompletionJul 2016
TodayJul 2026
First PostedJul 16, 2008
Enrollment StartSep 1, 2008
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 18.0 years ago
Interventions
Atomoxetinedrug
Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 weeks
Placebodrug
oral, daily, for 16 weeks